OC9:F:F-Omnicell Inc (EUR)

COMMON STOCK | Health Information Services |

Last Closing

USD 38.6

Change

+0.60 (+1.58)%

Market Cap

USD 1.77B

Volume

10.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
L0T:F GE HEALTHCARE TECH.INC.

-1.41 (-1.68%)

USD 38.43B
4YC:F M3 INC.

+0.15 (+1.72%)

USD 6.36B
2HE:F Healthequity Inc

+2.00 (+2.82%)

USD 6.07B
6HL0:F R1 RCM Inc

+0.10 (+0.80%)

USD 5.35B
9EH:F Evolent Health Inc

-1.00 (-3.82%)

USD 3.05B
1KJ:F 10X GENOMICS DL -00001

+0.31 (+1.57%)

USD 2.56B
6JM:F JMDC INC.

+0.40 (+1.42%)

USD 1.91B
4LL:F Teladoc Inc

+0.61 (+8.12%)

USD 1.34B
1XZ:F Ping An Healthcare and Technol..

-0.07 (-3.99%)

USD 1.34B
19P:F Phreesia Inc

+0.20 (+0.99%)

USD 1.18B

ETFs Containing OC9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.29% 71% C- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.29% 68% D+ 54% F
Trailing 12 Months  
Capital Gain -9.39% 57% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.39% 54% F 28% F
Trailing 5 Years  
Capital Gain -40.62% 45% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.62% 36% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -1.94% N/A N/A 39% F
Dividend Return -1.94% N/A N/A 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 58.47% N/A N/A 17% F
Risk Adjusted Return -3.32% N/A N/A 38% F
Market Capitalization 1.77B 89% A- 65% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector